Literature DB >> 27313106

Clinical guidelines: No more mistaken identities for botulinum neurotoxins.

Alberto Albanese1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27313106     DOI： 10.1038/nrneurol.2016.86

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  9 in total

1.  Practice parameters for the management of anal fissures (3rd revision).

Authors:  W Brian Perry; Sharon L Dykes; W Donald Buie; Janice F Rafferty
Journal:  Dis Colon Rectum       Date:  2010-08       Impact factor: 4.585

2.  Terminology for preparations of botulinum neurotoxins: what a difference a name makes.

Authors:  Alberto Albanese
Journal:  JAMA       Date:  2011-01-05       Impact factor: 56.272

3.  Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; J-M Gracies; H K Graham; J M Miyasaki; M Naumann; B Russman; L L Simpson; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

4.  Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  David M Simpson; Mark Hallett; Eric J Ashman; Cynthia L Comella; Mark W Green; Gary S Gronseth; Melissa J Armstrong; David Gloss; Sonja Potrebic; Joseph Jankovic; Barbara P Karp; Markus Naumann; Yuen T So; Stuart A Yablon
Journal:  Neurology       Date:  2016-04-18       Impact factor: 9.910

5.  EFNS guidelines on diagnosis and treatment of primary dystonias.

Authors:  A Albanese; F Asmus; K P Bhatia; A E Elia; B Elibol; G Filippini; T Gasser; J K Krauss; N Nardocci; A Newton; J Valls-Solé
Journal:  Eur J Neurol       Date:  2011-01       Impact factor: 6.089

6.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

7.  Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  M Naumann; Y So; C E Argoff; M K Childers; D D Dykstra; G S Gronseth; B Jabbari; H C Kaufmann; B Schurch; S D Silberstein; D M Simpson
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

Review 8.  Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.

Authors:  Alberto Albanese; Giovanni Abbruzzese; Dirk Dressler; Wojciech Duzynski; Svetlana Khatkova; Maria Jose Marti; Pablo Mir; Cesare Montecucco; Elena Moro; Michaela Pinter; Maja Relja; Emmanuel Roze; Inger Marie Skogseid; Sofiya Timerbaeva; Charalampos Tzoulis
Journal:  J Neurol       Date:  2015-04-01       Impact factor: 4.849

Review 9.  British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.

Authors:  Marie-Helene Marion; Miles Humberstone; Richard Grunewald; Sunil Wimalaratna
Journal:  Pract Neurol       Date:  2016-03-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.